New York, USA - September 4, 2024 - The recent public health emergency declared by the WHO over the monkeypox outbreak-the concerning clade 1b strain-has pushed global health agencies and researchers to accelerate their efforts in combating this emerging threat. Creative Biolabs is at the forefront of these efforts, offering cutting-edge services and solutions to support the development of anti-monkeypox drugs, leveraging their deep expertise to address the crisis.

"The clade 1b strain of the monkeypox virus has raised alarms due to its ability to spread between humans, including through sexual contact. This marks a significant departure from previous outbreaks where the virus was primarily transmitted through contact with wild animals," said a scientist at Creative Biolabs.

Creative Biolabs launched a suite of customized solutions to tackle the various mechanisms through which the monkeypox virus operates, covering everything from drug discovery targeting viral proteins and mechanisms to nucleic acid-based drug development, inhibitors, and analogues, as well as neutralizing antibodies and vaccine development.

Anti-monkeypox Drug Discovery Against Different Drug Targets

Creative Biolabs provides specialized services for discovering anti-monkeypox drugs targeting various viral proteins and mechanisms. By focusing on specific targets within the virus, the strategy is essential for creating effective therapeutics that can "strangle" the virus's ability to mutate and adapt. Prevalent targets include:

* Viral Nucleic Acid

* Viral Polymerase

* Protease

* Entry/Fusion Protein

* Interferon (IFN)

* Cellular Target

Nucleic Acid-Based Anti-monkeypox Drug Discovery

Nucleic acid-based therapies offer a versatile approach to combating viral infections like monkeypox, which can be divided into several different groups by their target molecules like viral proteins, viral or cellular nucleic acids, as well as viral nucleic acids or viral proteins. Creative Biolabs has developed approaches to designing and validating nucleic acid-based drugs, including RNA interference (RNAi) and antisense oligonucleotides, that can silence viral genes and prevent the virus from replicating.

Inhibitor or Analogue-Based Anti-monkeypox Drug Discovery

By discovering inhibitors or analogues that can block viral enzymes or mimic viral substrates, Creative Biolabs contributes to developing a powerful line of defense against monkeypox. This approach is crucial for further developing small molecule drugs that can be administered orally or intravenously to patients.

"Nucleoside and nucleotide analogues, if not specific to monkeypox DNA, could also affect the mitochondrial DNA of the hosts, thus resulting in side effects or toxicity, which is a factor we will consider, and also their drug resistance when supporting clients in drug discovery and screening." The scientist elaborated.

In addition to the mentioned drugs of different mechanisms, Creative Biolabs also supports neutralizing antibody-based anti-monkeypox drug discovery and discovering vaccine candidates, including the design of novel vaccine platforms and the evaluation of their efficacy and safety.

As the global health community races to contain this new strain of the monkeypox virus, Creative Biolabs stands ready to support researchers and pharmaceutical companies with the tools and expertise they need to develop life-saving therapies.

More Information: https://monkeypox.creative-biolabs.com

About

Creative Biolabs is a leading provider of cutting-edge solutions in the field of biotechnology, specializing in the development of innovative therapies and vaccines for infectious diseases.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://monkeypox.creative-biolabs.com